In the midst of an auto-injector shortage, the FDA approved a new U.S. competitor to the generic auto-injector options in August 2018.
The FDA gave Teva Pharmaceuticals the green light to begin producing a generic version of the branded EpiPen and EpiPen Jr.
This will be in addition to the authorized generic EpiPen, which Mylan began marketing in 2016.
“This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages,” FDA Commissioner Scott Gottlieb said in a statement.
“We’re applying our full resources to this important launch in the coming months and eager to being supplying the market,” Teva said in a statement.
The company has yet to provide details on launch timing or the generic’s price.
Read the full FDA announcement here.
Get more news from Allergic Living to your inbox.